denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: educational grants from Amgen and Dova Pharmaceuticals. Provided by Clinical Care Options, LLC.
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Biological, therapy sequence, Adult, Diseases, Bleeding and Clotting, bioengineering, Therapies, Combinations, cell regulation, platelets, Elderly, ITP, Pediatric, Biological Processes, Platelet Disorders, Technology and Procedures, Young Adult, Cell Lineage, Study Population, Thrombocytopenias, TKI, molecular interactions
Hematology Disease Topics & Pathways:
Biological, therapy sequence, Adult, Diseases, Bleeding and Clotting, bioengineering, Therapies, Combinations, cell regulation, platelets, Elderly, ITP, Pediatric, Biological Processes, Platelet Disorders, Technology and Procedures, Young Adult, Cell Lineage, Study Population, Thrombocytopenias, TKI, molecular interactions
Friday, December 4, 2020: 11:00 AM-2:00 PM
Chair:
David J. Kuter, MD, Massachusetts General Hospital
Disclosures:
Kuter: Protalex: Consultancy, Honoraria, Other, Research Funding; Sanofi (Genzyme): Consultancy, Honoraria; Zafgen: Consultancy, Honoraria; Shionogi: Consultancy, Honoraria; Kezar Life Sciences, Inc: Other, Research Funding; CRICO: Consultancy, Honoraria; Caremark: Consultancy, Honoraria; Genzyme: Consultancy, Honoraria; Immunovant: Consultancy, Honoraria; Alnylam: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Agios: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Daiichi Sankyo: Consultancy, Honoraria; Actelion (Syntimmune): Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Takeda (Bioverativ): Consultancy, Honoraria, Other, Research Funding; Rigel: Consultancy, Honoraria, Other, Research Funding; Dova: Consultancy, Honoraria; Merck Sharp Dohme: Consultancy, Honoraria; Momenta: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Platelet Disorder Support Association: Consultancy, Honoraria; UCB: Consultancy, Honoraria; Up-To-Date: Consultancy, Honoraria, Patents & Royalties; Bristol-Myers Squibb: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Argenx: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Amgen: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Shire: Consultancy, Honoraria; Protalix Biotherapeutics: Consultancy; Principia: Consultancy, Research Funding; Shionogi: Consultancy; Protalex: Consultancy, Honoraria, Research Funding; Immunovant: Other: Travel Expenses, Research Funding; Kyowa-Kirin: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Principia Biopharma: Consultancy, Honoraria, Other, Research Funding.
Speakers:
Keith R. McCrae, MD, Cleveland Clinic
and
Michael D Tarantino, MD, Bleeding & Clotting Disorders Institute
Disclosures:
McCrae: Dova: Consultancy; Novartis: Honoraria; Rigel: Consultancy; Momenta Pharmaceuticals: Consultancy. Tarantino: Octapharma: Membership on an entity's Board of Directors or advisory committees; CDC: Membership on an entity's Board of Directors or advisory committees; Grifols: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Genentech: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Pfizer: Other; Sobi: Membership on an entity's Board of Directors or advisory committees; Spark: Membership on an entity's Board of Directors or advisory committees; HRSA: Membership on an entity's Board of Directors or advisory committees; Takeda: Research Funding; NovoNordisk: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Biomarin: Membership on an entity's Board of Directors or advisory committees; Dova: Membership on an entity's Board of Directors or advisory committees.
New science has driven innovative medical practice in the recognition and management of immune thrombocytopenia (ITP). This webinar will focus on practical guidance such as treatment goals, therapeutic strategies for initial and second-line treatment, and toxicity management as well as review the latest research progress on new therapeutic approaches for ITP. Each section of the webinar will include a case review and didactic presentation by an expert faculty member followed by a moderated panel discussion and audience Q&A session. Expert faculty will discuss key clinical questions, available evidence, and challenges that affect therapeutic decisions as well as their personal treatment recommendations for each case. Throughout the webinar, learners will be able to vote on case scenarios and submit questions to the panel for their consideration. Discussion topics include:
- Optimizing the Management of Newly Diagnosed ITP
- Therapeutic Options for Patients With Previously Treated ITP
- Caring for Special Populations of Patients With ITP
See more of: Satellite Symposia